Back to All Events

Arthritis Advisory Committee

On July 12, 2016, the Arthritis Advisory Committee (AAC) supported, by a vote of 26-Yes to 0-No, with no abstentions, that the totality of the evidence supports licensure of ABP 501, submitted by Amgen, Inc. (Amgen), as a proposed biosimilar to AbbVie Inc.'s Humira (adalimumab).